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permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.SUMMARYIncreasing evidence suggests that elevated Ab42 fractions in the brain cause Alzheimer’s disease (AD). Although g-secretase modulators
(GSMs), including a set of nonsteroidal anti-inflammatory drugs (NSAIDs), were found to lower Ab42 in various model systems,
NSAID-based GSMs proved to be surprisingly inefficient in human clinical trials. Reasoning that the nonhuman and nonneuronal cells
typically used in pharmaceutical compound validation might not adequately reflect the drug responses of human neurons, we used
human pluripotent stem cell-derived neurons fromADpatients and unaffected donors to explore the efficacy of NSAID-based g-secretase
modulation. We found that pharmaceutically relevant concentrations of these GSMs that are clearly efficacious in conventional
nonneuronal cell models fail to elicit any effect on Ab42/Aß40 ratios in human neurons. Our work reveals resistance of human neurons
to NSAID-based g-secretase modulation, highlighting the need to validate compound efficacy directly in the human cell type affected by
the respective disease.INTRODUCTION
Alzheimer’s disease (AD) is a common and fatal neurode-
generative disorder. Currently, no effective drugs that can
stop, slow, or prevent disease progression are available.
Deposition of amyloid plaques consisting of aggregated
Ab peptides in the brain is a hallmark of the disease (Selkoe,
2001). The amyloid cascade hypothesis presumes that the
accumulation and oligomerization of Ab peptides trigger
a complex pathological cascade resulting in synaptic
dysfunction, tau hyperphosphorylation, and eventually
progressive neurodegeneration and dementia (Selkoe
et al., 2012). Ab is a proteolytic derivative of the transmem-
brane amyloid precursor protein (APP), which is sequen-
tially cleaved by b- and g-secretases in the amyloidogenic
processing pathway (Haass et al., 2012). Intramembranous
g-secretase cleavage of the C-terminal fragments of APP
(APP-CTF), which represent the immediate precursors of
Ab, results in multiple length variants of Ab (Haass et al.,
2012). Longer Ab variants such as Ab42 and Ab43 are
more prone to aggregation and thus are considered more
pathogenic than shorter ones such as Ab38 and Ab40
(Karran et al., 2011). Today, the peptide ratio of Ab42 to
Ab40 in the cerebrospinal fluid (CSF) represents the mostStem Cell Rsensitive and specific primary biomarker for AD and
inversely correlates with the age of disease onset in both
sporadic (Blennow et al., 2012) and familial (Kumar-Singh
et al., 2006) forms of AD. Mutations in APP or in the g-sec-
retase subunits presenilin-1 (PS1) and PS2 are the main
cause of autosomal-inherited early-onset forms of AD and
commonly lead to increased Ab42/Aß40 ratios and/or
overall elevated levels of Ab. These observations suggest
that misprocessing of APP with a consecutive increase of
Ab42/Aß40 ratios is characteristic of and, most probably,
causative for sporadic and familial AD (Wiltfang et al.,
2001). Based on this hypothesis, several antiamyloidogenic
drugs, including compounds that inhibit b- and g-secretase
activity, have been developed (Ghosh et al., 2012;
Imbimbo and Giardina, 2011). Interestingly, a subset of
nonsteroidal anti-inflammatory drugs (NSAIDs) were iden-
tified to act as g-secretase modulators (GSMs) that specif-
ically lower the production of Ab42 in favor of shorter Ab
isoforms by targeting g-secretase PS1 or its substrate APP
(Jumpertz et al., 2012; Kukar et al., 2008; Weggen et al.,
2001). Unfortunately, and despite solid preclinical data
acquired using transgenic animals and APP-transgenic
cell lines, NSAIDs such as flurbiprofen and indometacin
were not effective in delaying disease progression ineports j Vol. 1 j 491–498 j December 17, 2013 j ª2013 The Authors 491
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ical trials (de Jong et al., 2008; Eriksen et al., 2003; Green
et al., 2009; Imbimbo and Giardina, 2011; Vellas, 2010).
The reasons for these negative outcomes are speculative
and have been in part attributed to inappropriate study
design, as symptomatic AD patients were treated when
the disease may have already been irreversibly advanced
(Golde et al., 2011). Also, it remains unclear whether the
trialed GSMs indeed lowered Ab42 levels in the human
brain, leaving the important question as to whether g-sec-
retase modulation is a valid approach in AD therapy unre-
solved. Further, insufficient brain penetration of the tested
compounds, as well as a general failure of the amyloid
cascade hypothesis, has been considered (Golde et al.,
2011). Remarkably, the efficacy of GSMs in humanneurons
as the primary target cell type has never been directly
explored. Recent advances in neural differentiation of hu-
man embryonic stem cells (hESCs) and induced pluripo-
tent stem cells (iPSCs) enable the derivation of authentic
neuronal cultures to dissect the pathological mechanisms
relevant to AD and drug testing (Israel et al., 2012; Koch
et al., 2012; Mattis and Svendsen, 2011; Mertens et al.,
2013). Here, we used this approach to determine the effi-
cacy of NSAIDs previously employed in clinical GSM trials
in human neurons derived from iPSCs of patients with
familial AD and unaffected controls (Ctrl; Figure 1A).RESULTS AND DISCUSSION
Neurons Derived from Familial AD Patients Show
Elevated Ab42/Ab40 Ratios
To elucidate APP processing in human neurons from
various genetic backgrounds, we took advantage of our
recently described and highly standardized pluripotent
stem cell-derived, long-term self-renewing neural stem
cells (lt-NES cells), which consistently give rise to cultures
containing >70% functional human neurons (Falk et al.,
2012; Koch et al., 2009). We generated iPSCs from two
patients with familial AD (two clones each). Patient AD-1
(AD-1a and AD-1b) carries an A79V substitution in one
allele of the PS1 gene, which results in autosomal-domi-
nant AD (Larner and Doran, 2006). Patient AD-2 (AD-2a
and AD-2b) carries a K724N mutation in the intracytosolic
fragment of APP (for clinical details, see Table S1 available
online; Theuns et al., 2006). Characterization of the estab-
lished iPSC lines revealed sustained silencing of the reprog-
ramming transgenes, a normal karyotype, expression of
pluripotency markers, and formation of teratomas upon
in vivo transplantation (Figures S1A–S1D). The four AD-
patient-derived lines were subsequently differentiated
into lt-NES cells according to established protocols (Falk
et al., 2012; Koch et al., 2009). We further included lt-NES492 Stem Cell Reports j Vol. 1 j 491–498 j December 17, 2013 j ª2013 Thecells derived from reprogrammed fibroblasts from three un-
affected individuals (Ctrl-1: clone a and b; Ctrl-2: clone a
and b; Ctrl-3: clone a) (Falk et al., 2012; Koch et al., 2011)
and from the hESC lines I3 and I6 (hES-1 and hES-2)
(Koch et al., 2009). All Ctrl and AD lt-NES cell lines ex-
pressed the rosette-associated neuroectodermal markers
PLZF, Nestin, DACH1, SOX2, and apically accentuated
ZO-1 (Figure 1B). Familial AD mutations were confirmed
by sequencing genomic DNA from patient-derived lt-NES
cells (Figure S1E). Following differentiation for 4 weeks,
75%–85% of the cultures consisted of postmitotic neurons
that expressed b-III tubulin and MAP2ab, while <10% of
differentiated cells were positive for the glial marker glial
fibrillary acidic protein (GFAP; Figure 1B). We further de-
tected a consistent neuronal expression of PS1, APP, and
phosphorylated Tau protein (PHF1 antibody; Figure 1B).
Similarly to Ctrl neurons, which have been described previ-
ously (Falk et al., 2012; Koch et al., 2009), the AD lt-NES
cell-derived neurons developed mature functional proper-
ties, including the generation of action potentials upon
depolarization and the establishment of spontaneously
active synaptic circuitries (Figure 1C). The neuron-specific
APP695 variant and b- and g-secretase-associated genes
were expressed at comparable levels in the neuronal cul-
tures (Figure S1F). We detected no apparent variations in
neuronal differentiation efficiency, neuronal morphology,
basic electrophysiological function, or marker expression
in Ctrl and AD lt-NES cell-derived neurons.
Mutations in PS1 and APP are known to result in elevated
Ab42/Aß40 ratios in the CSF of familial AD patients
(Borchelt et al., 1996; Kumar-Singh et al., 2006). Hence,
we determined the levels of secreted Ab40 and Ab42 in
conditioned media of the generated Ctrl and AD neurons
by ELISA and calculated the Ab42/Aß40 ratio. No signifi-
cant difference in the Ab42/Aß40 ratio between hESC-
derived (0.092 ± 0.017) and Ctrl-iPSC-derived (0.096 ±
0.008) neurons was detected (Figure 2A). In contrast,
AD-1 and AD-2 neurons showed 37% and 89% increases
in Ab42/Aß40 ratios to 0.126 ± 0.001 and 0.174 ± 0.018,
respectively (Figure 2A). Interestingly, the increased
Ab42/Aß40 ratio in AD-1a neurons was solely attributable
to decreased secretion of total Ab40 by 26%, with Ab42
levels remaining comparable to those generated by hESC-
and Ctrl-iPSC-derived neurons (Figure 2B). AD-2a neurons
also exhibited a decrease in total Ab40 secretion by 31%,
but in addition showed a 33% increase in Ab42 secretion,
resulting in an overall higher increase in the Ab42/Aß40
ratio (Figure 2B). Thus, elevated Ab42/Aß40 ratios in
PS1(A79V) mutant neurons are likely due to a partial loss
of function in g-secretase function, while neurons from
the patient with the APP(K724N) mutation showed
decreased Ab40 production in combination with a gain
of function in Ab42 secretion (Koch et al., 2012).Authors
Figure 1. Human Neural Stem Cells and Neurons from Ctrl and AD-Patient-Specific iPSCs
(A) Experimental design: iPSCs were generated from dermal fibroblasts (Takahashi et al., 2007) and differentiated into lt-NES cell lines
(n = 11 [5 Ctrl-iPSC derived, 4 AD-iPSC derived, and 2 hESC derived]). Lt-NES cells were differentiated for 4 weeks into mature neuronal
cultures and subjected to GSM treatment and Ab ELISA measurements in the conditioned media.
(B) Immunocytochemical characterization of lt-NES cells and differentiated neuronal cultures. Lt-NES were stained for the neuro-
ectodermal stem cell markers Nestin, PLZF, DACH1, SOX2, and ZO-1. Differentiated cultures were analyzed for expression of b-III tubulin,
GFAP, MAP2ab, phosphorylated Tau (PHF1), PS1, and APP. Scale bars, 20 mm.
(C) Electrophysiological characterization of AD neurons. Representative traces depict multiple evoked action potentials during
current-clamp recording (n = 6) as well as whole-cell currents showing TTx/Cd2+-sensitive Na+ channel-mediated inward currents and
4-AP-sensitive K+ channel-mediated outward currents in response to depolarizing voltage steps (n = 7). Spontaneous postsynaptic
currents in neurons demonstrate functional synapses (n = 6).
See also Figure S1.
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mutations typically result in early-onset familial AD (age of
onset: 52–59 years), PS1(A79V) is considered a ‘‘weak’’
mutation with a slowly progressing pathogenesis, whereas
patients carrying the APP(K724N)mutation typically suffer
from a rapid pathogenesis (Larner and Doran, 2006).Stem Cell RNSAID-Based GSMs Can Lower Ab42/Ab40 Ratios
at High Concentrations
To explore how known NSAID-based GSMs impact endog-
enous g-secretase activity and thus influence the genera-
tion of Ab42 and Ab40 in human neurons, we first applied
a set of ten candidate compounds to hESC-derivedeports j Vol. 1 j 491–498 j December 17, 2013 j ª2013 The Authors 493
Figure 2. AD Patient iPSC-Derived Neu-
rons Show Elevated Ab42/Ab40 Ratios
that Can Be Lowered by High Concentra-
tions of NSAID-Based GSMs
(A) Endogenous secretion of Ab40 and Ab42
was analyzed by ELISA in conditioned media
of differentiated neuronal cultures, and
Ab42/Aß40 ratios were calculated.
(B) The total levels of Ab40 and Ab42 were
measured and normalized to the total
cellular protein amount of the respective
cultures.
(C) High-concentration screen: Ab42/Aß40
ratios of differentiated neuronal cultures
treated for 36 hr with 200 mM indometacin,
ibuprofen, diclofenac, or flurbiprofen. Bar
graphs show mean + SD; significance
values determined by ANOVA: *p % 0.01;
**p% 0.001.
ELISA measurements were performed at least
as biological triplicates.
See also Figure S2.
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levels were determined by ELISA after 36 hr of treatment.
We found that indometacin, ibuprofen, diclofenac, and
flurbiprofen significantly reduced the Ab42/Aß40 ratio at
200 mM, with indometacin and flurbiprofen exhibiting
the strongest effects (Figure S2A). Direct g-secretase inhibi-
tion by N-[N-(3,5-difluorophenacetyl)-1-alanyl]-S-phenyl-
glycine t-butyl ester (DAPT; 10 mM) or inhibition of the
g-secretase activating protein (GSAP) by imatinib
(10 mM) resulted in a strong decrease in both Ab variants.
Treatment with SC-560 (200 mM) specifically inhibited
Ab40 secretion, thereby leading to a 3-fold increased
Ab42/Aß40 ratio. Aspirin (250 mM) and naproxen
(200 mM), as well as the ROCK (Rho-associated coiled
coil forming protein serine/threonine kinase) inhibitor494 Stem Cell Reports j Vol. 1 j 491–498 j December 17, 2013 j ª2013 TheY-27632 (5 mM), had no detectable effects on the neurons
(Figures S2A and S2B). We next tested the four identified
NSAID-based GSMs on an extended set of Ctrl- and AD-
patient-derived neurons. Ibuprofen and diclofenac
(200 mM) reduced the Ab42/Aß40 ratio by 25.0%–36.5%
in all Ctrl- and AD-patient-derived neuronal cultures (Fig-
ure 2C). Flurbiprofen (200 mM) proved to be slightly more
potent, as it consistently reduced the ratio by 37.5%–
49.9% in all lines. Notably, the decrease in the Ab42/
Ab40 ratio induced by 200 mM indometacin varied
markedly between the cell lines, ranging between 10.0%
± 3.1% (AD-1a) and 75.0% ± 5.4% (Ctrl-1a). From these
data, we conclude that neuronal cultures from AD-patient-
derived iPSCs show pathologically altered Ab generation,
and that high concentrations of NSAID-based GSMsAuthors
Figure 3. Human Neurons from Ctrl- and AD-Patient-Derived iPSCs Are Resistant to Therapeutically Relevant Concentrations
of NSAID-Based GSMs that Failed in Clinical Trials
(A) Effect on the Ab42/Aß40 ratio of GSM concentrations that can be reached in the human CSF (Bannwarth et al., 1990; Kumpulainen
et al., 2010; Ritschel, 1999). Ctrl and AD neurons, as well as CHO-APP695, CHO-APPSWE, and HEK-APPSWE cells, were treated with increasing
concentrations of indometacin and Ab42/Aß40 ratios were measured.
(B) Total Ab40 and Ab42 levels in conditioned media of human neurons (Ctrl-1) and HEK-APPSWE and CHO-APP695 cells treated with
different concentrations of indometacin.
(C) Ab42/Aß40 ratios in human neurons (Ctrl-2) and HEK-APPSWE and CHO-APP695 cells in response to flurbiprofen. Data in (A)–(C) are
depicted as mean ± SEM.
(D) Ab42/Aß40 ratios of APP695-overexpressing hESC-derived neurons treated with flurbiprofen. All ELISA measurements were performed
at least as biological triplicates. Bar graph shows mean + SD. Significance values determined by ANOVA: *p% 0.01; **p% 0.001.
See also Figure S3.
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patient-derived neurons.
Human Neurons Do Not Respond to Therapeutically
Relevant Concentrations of GSMs
Based on pharmacokinetic studies in humans, therapeutic
dosages of most NSAIDs result in CSF concentrations in the
low micromolar range (Ritschel, 1999). For example,
maximum CSF levels can be expected to not exceed
30 mM for indometacin (Bannwarth et al., 1990; Ritschel,
1999) and 2 mM for flurbiprofen (Galasko et al., 2007;
Kumpulainen et al., 2010). Such low micromolar concen-
trations were sufficient to decrease Ab42/Aß40 ratios in
human APP-transgenic rodent cells (e.g., Chinese hamster
ovary [CHO] cells), human nonneural cell lines (e.g.,
human embryonic kidney [HEK] cells), and the brains of
transgenic mice. For example, 25 mM indometacin reduced
theAb42/Ab40 ratio by50% inCHO-APP cells and 1.3 mMStem Cell Rflurbiprofen reduced Ab42 levels by 80% in Tg2576 mice
(Eriksen et al., 2003; Weggen et al., 2001). Based on these
promising preclinical results, indometacin and flurbi-
profen were tested for their efficiency to delay cognitive
decline in human clinical trials. Yet, these GSMs failed to
show any significant effect on the course of the disease
compared with placebo controls (de Jong et al., 2008;
Green et al., 2009).
To evaluate the potency of these clinically failed NSAID-
based GSMs in modulating endogenous human neuronal
Ab generation at concentrations that can realistically
be achieved in the human brain, we treated differentiated
neuronal cultures from Ctrl and AD patients with
increasing concentrations of indometacin, and measured
Ab40 and Ab42 levels by ELISA in conditioned medium
after 36 hr (Figure 3A). As controls, CHO cells overex-
pressing human APP695, APPSWE (containing the K670N/
M671L double mutation), or HEK-APPSWE (Citron et al.,eports j Vol. 1 j 491–498 j December 17, 2013 j ª2013 The Authors 495
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25 mM indometacin sufficed to reduce the Ab42/Ab40 ratio
in CHO-APP cells by >50%, and by 22% in HEK-APPSWE
cells. Surprisingly, and in contrast to the APP-transgenic
cell lines, concentrations of up to 75 mM indometacin
had no significant effect on the ratio of Aß42 to Aß40
generated from endogenous APP in human neurons from
all five genetic backgrounds, including both AD patients
(Figure 3A; for separate graphs, see Figure S3A). Whereas
the total levels of Ab42 fromCHO-APP695 andHEK-APPSWE
cells selectively decreased in a concentration-dependent
manner, total secretion of Ab40 and Ab42 remained unaf-
fected in the human neuronal cultures (Figure 3B). Simi-
larly, human neurons also proved largely resistant to
clinically relevant concentrations of flurbiprofen, while
CHO-APP695 and HEK-APPSWE cells displayed a strong
dose-dependent response (Figure 3C; also see Figure S3B).
To exclude interference of culture-medium ingredients,
we tested hESC- and iPSC-derived neurons in parallel
with HEK-APP695 cells in the identical serum-containing
medium. Under these conditions as well, human neurons
exhibited a specific resistance to GSM treatment (Fig-
ure S3C). In order to detect a possible GSM-inactivating
activity of human neurons, we preincubated drug-contain-
ing medium (indometacin or flurbiprofen; both 75 mM) on
human neurons or CHOWT cells before transferring it to
CHO-APPSWE. We found that preincubation on neurons
or CHOWT did not reduce the drugs’ ability to decrease
the Aß42/Aß40 ratio in CHO-APPSWE cells (Figure S3D).
We next asked whether artificially high protein levels of
APP/APP-CTFs might provoke an abnormally amplified
GSM effect that is not observed at endogenous expression
levels. To test this, we generated transgenic lt-NES cells
that conditionally overexpress APP695 when treated with
doxycycline (tetOn). Transgenic APP695 overexpression
was induced following 4 weeks of differentiation. Interest-
ingly, overexpressing hES-1-APP695 neurons significantly
responded to 75 mM flurbiprofen, whereas nontransgenic
hES-1 neurons remained inert (Figure 3D). However, the
effect was mild compared with that detected in CHO-
APP695 cells and was not observed when the APP over-
expressing neurons were treated with 25 mM or 75 mM
indometacin (Figure S3E). A plausible explanation might
be that the APP protein levels achieved in transgenic
human neurons are still significantly lower than those in
CHO cells and thus are only partially sufficient to evoke
the pronounced effect seen in tumor cell lines (Figure S3F).
Although increased GSM responses can be triggered by
exaggerated APP levels in neurons, the actual cause of
the low GSM responsiveness of human neurons might be
complex. For example, it could involve specific subcellular
localizations and posttranslational modifications of the
g-secretase/APP complex and/or interactors that may be496 Stem Cell Reports j Vol. 1 j 491–498 j December 17, 2013 j ª2013 Thespecifically regulated in human neurons, such as
g-secretase activating protein (GSAP) and CD147 (Rajen-
dran et al., 2010). Species-specific effects may also con-
tribute to this phenomenon, as human HEK cells consis-
tently showed weaker responses to GSMs as compared
with rodent CHO cells.
Taken together, our experiments reveal a cell-type-
specific resistance of human neurons to pharmacologically
relevant concentrations of known NSAID-based GSMs that
stands in sharp contrast towidely used conventionalmodel
and drug-screening systems. Thus, it appears to be conceiv-
able that data generated using APP-overexpressing cell lines
and APP-transgenic mouse models have led to an overesti-
mation of GSM efficacy in human neurons, a hypothesis
that is supported by the clinical failure of this class of com-
pounds. Extrapolating from our data, we conclude that
much higher CSF concentrations of these NSAID-based
GSMs would have been required to elicit beneficial effects
in the human CNS. Our findings also strongly underline
the importance and necessity of assessing compound effi-
cacy in the appropriate human target cell type. Although
in the past this route has been restricted due to the lack
of primary tissue, the availability of hESCs and iPSCs now
provides unprecedented opportunities for drug screening
and preclinical compound validation in cell type-,
disease-, and even patient-specific cell culture models.EXPERIMENTAL PROCEDURES
Culture and Differentiation of lt-NES Cells
Lt-NES cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM)/F12, 2 mM L-glutamine, 1.6 g/l glucose,
0.1 mg/ml penicillin/streptomycin, N2 supplement (high trans-
ferrin; PAA), B27 (1 ml/ml; Life Technologies), and fibroblast
growth factor 2 (FGF2) and epidermal growth factor (EGF; both
10 ng/ml; R&D Systems) on tissue culture plates coated with
poly-L-ornithine/laminin (both Sigma), and passaged every
3–4 days. Neuronal differentiation was induced by withdrawal of
FGF2 and EGF in differentiation media (Neurobasal medium
supplemented with B27 [1:50; Life Technologies] and DMEM/
F12 supplemented with N2 mixed at a 1:1 ratio and containing
300 ng/ml cyclic AMP) that was exchanged every second day
(Koch et al., 2009).
The study was approved by the local ethics committee.Treatment of Cells with GSMs and Other Small
Molecules
Cells were pretreated for 12 hr withmediumcontaining the respec-
tive compound. Then the drug-containing medium was replaced
and, 24 hr later, subjected to ELISAmeasurements. Stock solutions
were as follows: ibuprofen (200 mM; Alexis Biochemicals), dic-
lofenac (200 mM), naproxen (200 mM), flurbiprofen (200 mM),
aspirin (250 mM), indometacin (50 mM; Cayman Chemical),
SC-560 (200 mM), imatinib (10 mM; Novartis; all in ethanol),Authors
Stem Cell Reports
Drug Resistance of Human iPSC-Derived NeuronsDAPT (5mM; SigmaAldrich;DMSO), andROCK inhibitor (25mM;
Sigma Aldrich; DMSO).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, three figures, and one table and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
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